Duloxetine for patients with diabetic peripheral neuropathic pain: A 6-month open-label safety study

Pain Medicine

Volumn 7, Issue 5, 2006, Pages 373-385

  Raskin, Joel ^a   Wang, Fujun ^a   Pritchett, Yili Lu ^a,b   Goldstein, David J ^c  

^a ELI LILLY AND COMPANY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Diabetic peripheral neuropathic pain; Duloxetine; Pain

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANTIEMETIC AGENT; ATORVASTATIN; CARBAMAZEPINE; CHLORAL HYDRATE; DULOXETINE; ENALAPRIL; GABAPENTIN; GLIBENCLAMIDE; HYPNOTIC AGENT; INSULIN; METFORMIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; STEROID;

ACUTE HEART INFARCTION; ADULT; AGED; ANALGESIA; ANOREXIA; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; BRIEF PAIN INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHIC PAIN; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SKIN ULCER; SOMNOLENCE; SWEAT GLAND DISEASE; TACHYCARDIA; TREATMENT DURATION; VOMITING; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; AGED; ARRHYTHMIA; ARRHYTHMIAS, CARDIAC; BLOOD PRESSURE; DIABETIC NEUROPATHIES; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG-INDUCED LIVER INJURY; FEMALE; HEART RATE; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; NAUSEA; SEROTONIN UPTAKE INHIBITORS; TACHYCARDIA; THIOPHENES; TREATMENT OUTCOME;

EID: 33749077183     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2006.00207.x     Document Type: Article

References (53)

1. National Diabetes Information Clearinghouse (NDIC). National Diabetes Statistics: Total Prevalence of Diabetes in the United States, All Ages, 2002. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/ index.htm#7 (accessed October 18, 2004).
2. Eastman RC. Neuropathy in diabetes. In: Harris MI, Cowie CC, Stern MP, et al., eds. Diabetes in America, 2nd edition. NIH Publication no. 95-146. Bethesda: National Diabetes Information Clearinghouse; 1995: 339-47.
3. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-24.
4. Basbaum AI, Fields HL. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984; 7: 309-38.
5. Clark FM, Proudfit HK. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: Anatomical evidence that A5 neurons modulate nociception. Brain Res 1993; 616: 200-10.
6. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 1997; 14: 2-31.
7. Hodge CJ Jr, Apkarian AV, Owen MP, Hanson BS. Changes in the effects of stimulation of locus coeruleus and nucleus raphe magnus following dorsal rhizotomy. Brain Res 1983; 288: 325-9.
8. Coderre TJ, Katz J. Peripheral and central hyperexcitability: Differential signs and symptoms in persistent pain. Behav Brain Sci 1997; 20: 404-19, discussion 435-513.
9. Poncelet AN. Diabetic polyneuropathy. Risk factors, patterns of presentation, diagnosis, and treatment. Geriatrics 2003; 58: 16-8, 24-5, 30.
10. Magni G. The use of antidepressants in the treatment of chronic pain. A review of the current evidence. Drugs 1991; 42: 730-48.
11. Lynch ME. Antidepressants as analgesics: A review of randomized controlled trials. J Psychiatry Neurosci 2001; 26: 30-6.
12. Monks R, Mersky H. Psychotropic drugs. In: Wall PD, Melzack R, eds. Textbook of Pain, 2nd edition. Edinburgh: Churchill Livingstone; 1989: 702-21.
13. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: A review of current literature. Harv Rev Psychiatry 2000; 7: 257-77.
14. Barkin RL, Fawcett J. The management challenges of chronic pain: The role of antidepressants. Am J Ther 2000; 7: 31-47.
15. Wong DT, Bymaster FP, Mayle DA, etal. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993; 8: 23-33.
16. Karpa KD, Cavanaugh JE, Lakoski JM. Duloxetine pharmacology: Profile of a dual monamine modulator. CNS Drug Rev 2002; 8: 361-76.
17. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36: 383-90.
18. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63: 308-15.
19. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry 2002; 63: 225-31.
20. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 1237-44.
21. Goldstein DJ, Lu Y, Detke MJ, etal. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24: 389-99.
22. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-18.
23. Raskin J, Pritchett YL, Wang F, etal. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346-56.
24. Feldman EL, Stevens MJ, Thomas PK, etal. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281-9.
25. Diabetes Control and Complications Trial Research Group (DCCT). Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271-86.
26. Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46. Erratum in: Arch Intern Med 1998;158:573.
27. Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129-38.
28. National Institute of Mental Health (NIMH). ECDEU Assessment Manual for Psychopharmacology, revised 1976. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976: 217-22, 313 -31.
29. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004; 63: 2104-10.
30. Backonja M, Beydoun A, Edwards KR, etal. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998; 280: 1831-6.
31. Backonja MM, Stacey B. Neuropathic pain symptoms relative to overall pain rating. J Pain 2004; 5: 491-7.
32. Ries M, Mengel E, Kutschke G, et al. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 2003; 26: 413-4.
33. ICH Steering Committee. ICH Harmonised Tripartite Guideline. The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions, E1. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Recommended for Adoption at Step 4 of the ICH Process on 27 October 1994 by the ICH Steering Committee. Available at: http://www.biologicsconsulting.com/docs/ich/ICHE1.pdf (accessed June 9, 2005).
34. Nemeroff CB, Schatzberg AF, Goldstein DJ, etal. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36: 106-32.
35. Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Immediate switching of antidepressant therapy: Results from a clinical trial of duloxetine. Ann Clin Psychiatry 2005; 17: 259-68.
36. Feighner JP. Cardiovascular safety in depressed patients: Focus on venlafaxine. J Clin Psychiatry 1995; 56: 574-9.
37. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 1993; 269: 2673-5.
38. Alvarez W Jr, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: A review of the literature. Pharmacotherapy 2003; 23: 754-71.
39. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004; 14: 457-70.
40. O'Moore-Sullivan TM, Prins JB. Thiazolidinediones and type 2 diabetes: New drugs for an old disease. Med J Aust 2002; 176: 381-6.
41. Wagstaff AJ, Goa KL. Rosiglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-37.
42. Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004; 65 (suppl): S23-7.
43. Joss JD. Tricyclic antidepressant use in diabetic neuropathy. Ann Pharmacother 1999; 33: 996-1000.
44. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25: 81-104.
45. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589-96.
46. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-6.
47. Sindrup SH, Gram LF, Skjold T, et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol 1990; 30: 683-91.
48. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931-7.
49. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents. Am J Med 2000; 108: 2-8.
50. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: An open-label pilot study. J Pain Symptom Manage 2000; 20: 280-5.
51. Harden RN. Chronic neuropathic pain. Mechanisms, diagnosis, and treatment. Neurologist 2005; 11 (2): 111-22.
52. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 2000; 60 (5): 1029-52.
53. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999 December; 83 (3): 389-400.